Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease.
OBJECTIVES: We evaluated urinary β2-microglobulin (U-β2M) as a prognostic and treatment-associated marker in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) with interstitial lung disease (ILD). METHODS: We retrospectively identified 68 patients with MDA5-DM admitted between January 2004 and March 2023. After excluding five patients with confirmed or indeterminate outcomes unrelated to MDA5-DM, 63 patients were included (20 deaths, 43 survivors); baseline U-β2M was available in 52 patients (16 deaths, 36 survivors). Pre-treatment levels, longitudinal changes, and correlations with serum ferritin and anti-MDA5 antibody titres were evaluated. RESULTS: At admission, U-β2M levels were significantly higher in the deceased group (p = 0.011). U-β2M predicted mortality (area under the curve 0.72), comparable to serum ferritin and anti-MDA5 antibody titres (0.68 and 0.69), and significantly higher than serum Krebs von den Lungen-6 (KL-6) (0.50; p = 0.0394). U-β2M correlated with anti-MDA5 antibody titres (p < 0.0001) and serum ferritin (p < 0.0001). Post-treatment U-β2M decreased in survivors (p = 0.009) but increased in deceased patients (p = 0.009). Serum ferritin did not change significantly (p = 0.086 and p = 0.782, respectively); KL-6 did not change significantly in survivors (p = 0.059) but increased in the deceased group (p < 0.0001). CONCLUSION: U-β2M is a promising, non-invasive prognostic and treatment-associated marker for MDA5-DM with ILD, showing more pronounced longitudinal change than serum ferritin and KL-6. However, given the retrospective, single-center design of this study, prospective validation in larger cohorts is warranted.
Authors
- Takao Nagashima (ORCID: https://orcid.org/0000-0003-0620-6774)
- Kojiro Sato
- Jun Nakamura
Institutions
- Jichi Medical University (JP)
- Jichi Medical University Saitama Medical Center (JP)
- Saitama Medical Center, Saitama Medical University (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/rheumatology/keag632
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00